These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 31424370)

  • 1. Recent Progress in the Development of HIV-1 Entry Inhibitors: From Small Molecules to Potent Anti-HIV Agents.
    Suttisintong K; Kaewchangwat N; Thanayupong E; Nerungsi C; Srikun O; Pungpo P
    Curr Top Med Chem; 2019; 19(18):1599-1620. PubMed ID: 31424370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of Small-molecule HIV Entry Inhibitors Specifically Targeting gp120 or gp41.
    Lu L; Yu F; Cai L; Debnath AK; Jiang S
    Curr Top Med Chem; 2016; 16(10):1074-90. PubMed ID: 26324044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV-1 Entry Inhibitors: A Review of Experimental and Computational Studies.
    Mostashari Rad T; Saghaie L; Fassihi A
    Chem Biodivers; 2018 Oct; 15(10):e1800159. PubMed ID: 30027572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Discovery and Development of Oxalamide and Pyrrole Small Molecule Inhibitors of gp120 and HIV Entry - A Review.
    Motati DR; Uredi D; Watkins EB
    Curr Top Med Chem; 2019; 19(18):1650-1675. PubMed ID: 31424369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV entry inhibitors: progress in development and application.
    Lai WH; Huang L; Chen CH
    Yao Xue Xue Bao; 2010 Feb; 45(2):131-40. PubMed ID: 21348414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of HIV-1 fusion inhibitors targeting gp41.
    Lu K; Asyifah MR; Shao F; Zhang D
    Curr Med Chem; 2014 Jun; 21(17):1976-96. PubMed ID: 24350848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-based design, synthesis and validation of CD4-mimetic small molecule inhibitors of HIV-1 entry: conversion of a viral entry agonist to an antagonist.
    Courter JR; Madani N; Sodroski J; Schön A; Freire E; Kwong PD; Hendrickson WA; Chaiken IM; LaLonde JM; Smith AB
    Acc Chem Res; 2014 Apr; 47(4):1228-37. PubMed ID: 24502450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progress in targeting HIV-1 entry.
    Ryser HJ; Flückiger R
    Drug Discov Today; 2005 Aug; 10(16):1085-94. PubMed ID: 16182193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of anti-HIV agents targeting dynamic supramolecular mechanism: entry and fusion inhibitors based on CXCR4/CCR5 antagonists and gp41-C34-remodeling peptides.
    Tamamura H; Otaka A; Fujii N
    Curr HIV Res; 2005 Oct; 3(4):289-301. PubMed ID: 16250877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The C4 region as a target for HIV entry inhibitors--NMR mapping of the interacting segments of T20 and gp120.
    Moseri A; Biron Z; Arshava B; Scherf T; Naider F; Anglister J
    FEBS J; 2015 Dec; 282(24):4643-57. PubMed ID: 26432362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Virus entry as a target for anti-HIV intervention.
    Esté JA
    Curr Med Chem; 2003 Sep; 10(17):1617-32. PubMed ID: 12871111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Small-Molecule CD4 Mimics Containing Mono-cyclohexyl Moieties as HIV Entry Inhibitors.
    Ohashi N; Harada S; Mizuguchi T; Irahara Y; Yamada Y; Kotani M; Nomura W; Matsushita S; Yoshimura K; Tamamura H
    ChemMedChem; 2016 Apr; 11(8):940-6. PubMed ID: 26891461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A targeted covalent small molecule inhibitor of HIV-1 fusion.
    Zhou G; He L; Li KH; Pedroso CCS; Gochin M
    Chem Commun (Camb); 2021 May; 57(37):4528-4531. PubMed ID: 33956029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Small-molecule HIV-1 entry inhibitors targeting gp120 and gp41: a patent review (2010-2015).
    Li W; Lu L; Li W; Jiang S
    Expert Opin Ther Pat; 2017 Jun; 27(6):707-719. PubMed ID: 28076686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 2-Aminothiazolones as anti-HIV agents that act as gp120-CD4 inhibitors.
    Tiberi M; Tintori C; Ceresola ER; Fazi R; Zamperini C; Calandro P; Franchi L; Selvaraj M; Botta L; Sampaolo M; Saita D; Ferrarese R; Clementi M; Canducci F; Botta M
    Antimicrob Agents Chemother; 2014 Jun; 58(6):3043-52. PubMed ID: 24614386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Viral surface glycoproteins, gp120 and gp41, as potential drug targets against HIV-1: brief overview one quarter of a century past the approval of zidovudine, the first anti-retroviral drug.
    Teixeira C; Gomes JR; Gomes P; Maurel F; Barbault F
    Eur J Med Chem; 2011 Apr; 46(4):979-92. PubMed ID: 21345545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Polyanionic inhibitors of HIV adsorption].
    Baranova EO; Shastina NS; Shvets VI
    Bioorg Khim; 2011; 37(5):592-608. PubMed ID: 22332354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploratory studies on soluble small molecule CD4 mimics as HIV entry inhibitors.
    Tsuji K; Kobayakawa T; Konno K; Masuda A; Takahashi K; Ohashi N; Yoshimura K; Kuwata T; Matsushita S; Harada S; Tamamura H
    Bioorg Med Chem; 2022 Feb; 56():116616. PubMed ID: 35063895
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting HIV-1 gp41-induced fusion and pathogenesis for anti-viral therapy.
    Garg H; Viard M; Jacobs A; Blumenthal R
    Curr Top Med Chem; 2011 Dec; 11(24):2947-58. PubMed ID: 22044225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV-1 gp41: mediator of fusion and target for inhibition.
    Weiss CD
    AIDS Rev; 2003; 5(4):214-21. PubMed ID: 15012000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.